Physician profile
Patrick Michael Kurecka
NPI 1346775228
$1,113.08
in general payments reported to CMS, 2019-2025
15 companies · $279 in 2025
The $279 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $438 · 2023: $160 · 2024: $236 · 2025: $279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $675.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $674.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $316.89 | 2022-2025 | Corevalve Evolut R |
| Bard Peripheral Vascular, INC. | $114.45 | 2024 | Rotarexs 6 F X 135 Cm |
| Heartflow, INC. | $110.87 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $104.17 | 2023-2025 | Lifevest |
| Boston Scientific Corporation | $78.76 | 2024 | |
| Abiomed | $76.70 | 2022 | |
| Organon LLC | $69.56 | 2022 | |
| Baxter Healthcare | $55.79 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Atricure, INC. | $54.52 | 2023-2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Astrazeneca Pharmaceuticals LP | $45.78 | 2023-2024 | Wainua, Farxiga |
| Novo Nordisk INC | $18.75 | 2025 | |
| Cardiva Medical, INC. | $17.67 | 2022 | |
| Novartis Pharmaceuticals Corporation | $17.22 | 2023 | |
| Lexicon Pharmaceuticals, INC. | $16.41 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.54 | 2023 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Kurecka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.